“EARLY-MOVER ADVANTAGE” VERSUS “SECOND TAKES MOST” DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR
“EARLY-MOVER ADVANTAGE” VERSUS “SECOND TAKES MOST” DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR
Adrian NEGREA, Daniel-Nicu IONAȘ
Department of International Business, Faculty of Economics, University of Oradea, Oradea, Romania
ngr_adrian@yahoo.com
ionasdanieln@gmail.com
Abstract: The pharmaceutical landscape for obesity treatments is defined by extreme market volatility and risks, where clinical trial data and regulatory milestones serve as the primary catalysts for multi-billion dollar shifts in valuation. Recent market shifts illustrate a transition from early-mover advantages to a regime dictated by clinical superiority and manufacturing scale, as evidenced by Eli Lilly surpassing Novo Nordisk in market capitalization; while analysis of various market scenarios reveals that while positive Phase 2/3 data can double the value of clinical-stage companies, established leaders face significant risks from “multiple compression,” competitive displacement, and the emergence of lower-priced copycat medications. Furthermore, a strategic focus on the GLP-1/GIP receptor space is currently rewarded with valuation premiums; while resource diversification often leads to institutional divestment and stagnant growth; which sometimes can lead to market loss.
Keywords: Obesity Therapeutics; GLP-1/GIP; Pharmaceutical Valuation; Clinical Trial Catalysts; Market Capitalization; Competitive Displacement; Multiple Compression.
JEL Classification: L65; G14; O32; L11.
